EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Clinical guidance for cannabidiol‐associated hepatotoxicity: A narrative review

Lauren Eadie, Lindsay A Lo, Michael Boivin, Jagpaul K Deol, Caroline A MacCallum iD

Journal of Gastroenterology and Hepatology · 2024-12 · 39 (12) · 2522-2532

DOI: 10.1111/jgh.16730 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 03.09.2024. Verfasst von Lauren Eadie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Cannabidiol, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is increasing evidence that cannabidiol (CBD) use is associated with clinically significant liver enzyme (LE) elevations and drug‐induced liver injury (DILI). The proportion of LE elevations and DILI events reported in the literature meet the Council for International Organizations of Medical Sciences' (CIOMS) classification of a common adverse drug reaction. However, these potential adverse events are unknown to many clinicians and may be overlooked. The increasing use of CBD for both medical and non‐medical use necessitates clear direction in the diagnosis and management of CBD‐associated hepatotoxicity. To our knowledge, no such clinical guidance currently exists. For people presenting with elevated LEs, CBD use should be screened for and be considered in the differential diagnosis. This narrative review will provide clinicians with guidance in the prevention, detection, and management of CBD‐related hepatotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolChemical and Drug Induced Liver InjuryHumansPractice Guidelines as TopicDiagnosis, DifferentialLiver

Stichwörter der Autor:innen

Adverse eventsCBDCannabidiolCannabisDILIDrug‐induced injuryHepatotoxicityLiverSafety

Substanzen

Cannabidiol

Autor:innen und Institutionen

  • Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • School of Medicine, Queen's University, Kingston, Ontario, Canada.
  • CommPharm Consulting, Barrie, Ontario, Canada.
  • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Caroline A MacCallum

Zitieren

APA

Eadie, L., Lo, L. A., Boivin, M., Deol, J. K., & MacCallum, C. A. (2024). Clinical guidance for cannabidiol‐associated hepatotoxicity: A narrative review. Journal of Gastroenterology and Hepatology, 39(12), 2522-2532. https://doi.org/10.1111/jgh.16730

Vancouver

Eadie L, Lo LA, Boivin M, Deol JK, MacCallum CA. Clinical guidance for cannabidiol‐associated hepatotoxicity: A narrative review. Journal of Gastroenterology and Hepatology. 2024;39(12):2522-2532. doi:10.1111/jgh.16730

BibTeX
@article{Eadie2024,
  author = {Eadie, Lauren and Lo, Lindsay A and Boivin, Michael and Deol, Jagpaul K and MacCallum, Caroline A},
  title = {Clinical guidance for cannabidiol‐associated hepatotoxicity: A narrative review},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  volume = {39},
  number = {12},
  pages = {2522--2532},
  doi = {10.1111/jgh.16730}
}
Kostenlos starten →